Laurent Peyrin-Biroulet is Professor of Medicine and Head of the inflammatory bowel disease (IBD) unit (Inserm U1256 NGERE) at Nancy University Hospital, France. Upon receiving his medical degree and PhD, he undertook a postdoctoral fellowship at the IBD Centre in Lille, France (2007), before taking a research position at the Mayo Clinic in Rochester, MN, USA (2008-2009). He received a Rising Star award in 2008 from the United European Gastroenterology Federation (UEGF).
Professor Peyrin-Biroulet is the President of the GETAID (Groupe d'Etude Thérapeutique des Affections Inﬂammatoires du tube Digestif) and former President of the Scientific Committee of the French association of IBD patients (AFA). He is the former Chair of the IBD Committee of the French Society of Digestive Endoscopy (SFED) and the Clinical Trials Task Force of the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) and was a member of the UEGF Scientific Committee (2011-2014). He is the current President of the European Crohn’s and Colitis Organisation (ECCO) and the current Scientific Secretary of IOIBD. He was the coordinator for the development of the first Disability Index for IBD and of the treat-to-target (STRIDE) recommendations and proposed the first definitions of early Crohn’s disease and of disease severity for IBD. Professor Peyrin-Biroulet is the co-founder of the Spectrum consortium and President of the Ibd CAncer and seRious infections in Europe (ICARE) project.
Professor Peyrin-Biroulet has authored more than 600 peer-reviewed articles and more than 200 non-peer-reviewed articles. He serves as a reviewer for several international journals, has held positions as an associate editor for Digestive and Liver Disease (2013-2017) and Clinical Gastroenterology and Hepatology (2017-present), and is a member of the editorial board for Alimentary Pharmacology & Therapeutics, Journal of Crohn’s and Colitis, Expert Review of Clinical Immunology, and Gut. Professor Peyrin-Biroulet is a staff contributor for the Selected Summary section of Gastroenterology. He joined the editorial team of the Cochrane Inflammatory Bowel Diseases and Functional Bowel Disorders (IBD/FBD) Review Group in 2014 and served as Councillor to the Immunology, Microbiology and IBD section of the American Gastroenterological Association (AGA) Institute Council between 2014 and 2016.EM-39423 - Date of preparation: August 2020